ProCE Banner Activity

CME

Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices

Multimedia
Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentation on key data and treatment paradigms for advanced HCC.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: January 26, 2021

Expiration: January 25, 2022

No longer available for credit.

Share

Faculty

Mark Yarchoan

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Genentech, a member of the Roche Group

Lilly

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for oncologists, hepatologists, gastroenterologists, radiologists, and other healthcare providers who care for patients with advanced HCC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Explore the current status of predictive biomarkers for identification and selection of patients for novel therapies and emerging molecular/immunologic classifications that could inform future biomarker-enriched clinical trial design, enabling precision oncology care in HCC
  • Select optimal, individualized locoregional treatment for patients with HCC based on recent advances and evolving best practices to maximize clinical outcomes
  • Review recent therapeutic advances and FDA approvals of novel systemic treatments (including targeted and immunotherapeutic agents) for patients with newly diagnosed and relapsed/refractory advanced HCC and integrate this information into clinical practice
  • Plan therapeutic strategies that optimize the selection/sequence of therapies to provide the best outcome to patients with HCC in the first-line setting and for patients with advanced HCC and treatment for patients with HCC that has progressed on or after 1 or multiple lines of therapy, taking into consideration the available clinical evidence, known agent toxicity/ tolerability profiles, expert recommendations, and patient preferences
  • Assess the safety profiles of targeted therapies and checkpoint inhibitors used in the management of HCC
  • Counsel patients to help them understand their treatment options and to be proactive, knowledgeable learners in their care

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Mark Yarchoan, MD, has disclosed that he has received consulting fees from AstraZeneca, Eisai, Exelixis, and Genentech.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2021, through January 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate recent findings into the treatment of patients with hepatocellular carcinoma.